Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 6, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Oct 5, 2026Reported sale · Form 4Olivier Loeillot, Chief Executive Officer · $238.3KOpen the filing ↗
- Oct 5, 2026Reported sale · Form 4Olivier Loeillot, Chief Executive Officer · $798.4KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record1,29219 flagged findings
Reported transactions (Form 4)80since Dec 5, 2024 · and 5 other holdings
Corporate events (8-K)30since May 31, 2019
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-06share offering or dilution eventrecentOpen filing ↗“…December 31, 2025, the fair value of the Company’s 1.00% Convertible Senior Notes due 2028 (the “2023 Notes”) wa s $ 607.4 million…”
+1 more passage from the same document
- “…(Amounts in thousands) Employee compensation $ 26,278 $ 40,141 Deferred revenue 18,308 14,609 Income taxes payable 897 3,592 Other…”
- 2026-05-06capital return (buybacks/dividends)recentOpen filing ↗“…acquire additional bioprocessing products; • the scope of and progress made in our R&D activities; • the scope of investment in our…”
+1 more passage from the same document
- “…additional bioprocessing products; • the scope of and progress made in our R&D activities; • the scope of investment in our…”
- 2026-05-06merger or acquisition eventrecentOpen filing ↗“…available for issuance under the 2018 Plan. At March 31, 2026, there were 973,674 shares available for future grants under the 2018…”
- 2026-02-26share offering or dilution eventrecentOpen filing ↗“…not have the ability to raise the funds necessary to settle for cash conversions of our Notes or to repurchase the Notes for cash…”
+1 more passage from the same document
- “…our business and results of operations. In December 2023, we incurred significant indebtedness with the issuance of $600.0…”
- 2026-02-26export control restrictionsrecentOpen filing ↗“…or provision of certain products and services to certain countries, governments, and persons, including those administered by the…”
+1 more passage from the same document
- “…to prevent our products and services from being exported in violation of these laws, we cannot guarantee that the…”
- 2026-02-26capital return (buybacks/dividends)recentOpen filing ↗“…to forecast, the potential future performance of our common stock. Issuer Purchases of Equity Securities In June 2008, the Board…”
+1 more passage from the same document
- “…any shares of common stock under the 2008 Repurchase Program during the year ended December 31, 2025. In prior years, we…”
- 2026-02-26Department of Justice inquiryrecentOpen filing ↗“…application of its Health Breach Notification Rule. Through executive and legislative action, the federal government has also taken…”
- 2026-02-26merger or acquisition eventrecentOpen filing ↗“…to improbable) in accordance with ASC 718, because vesting conditions before and after June 12, 2024 were improbable of being…”
+1 more passage from the same document
- “…to satisfy the contingent consideration obligation established under the FlexBiosys Agreement, which the Company entered into as part…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 1,292)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 8, 26Form 4 ↗Insider transaction
- Oct 7, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 13.0% · event on Sep 30, 26 · amendment
- Oct 6, 26Form 4 ↗Insider transaction
- Oct 6, 268-K ↗Current report · Completed an acquisition or disposal
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Oct 5, 26Form 144 ↗Notice of proposed sale
- Oct 5, 26Form 144 ↗Notice of proposed sale
- Oct 5, 26Form 4 ↗Insider transaction
- Sep 30, 26Form 425 ↗Merger, acquisition or tender offer
- Sep 24, 26Form 144 ↗Notice of proposed sale
- Sep 22, 26Form 4 ↗Insider transaction
- Sep 21, 26Form 144 ↗Notice of proposed sale
- Sep 15, 268-K ↗Current report · A senior executive left or was appointed
- Sep 8, 26Form 4 ↗Insider transaction
- Sep 8, 26Form 425 ↗Merger, acquisition or tender offer
- Sep 8, 268-K ↗Current report · Other events
- Sep 4, 26Form 144 ↗Notice of proposed sale
- Sep 4, 26424B3 ↗Securities offering
- Sep 4, 26S-4/A ↗Merger, acquisition or tender offer · amendment
- Sep 2, 26Form 4 ↗Insider transaction
- Aug 25, 26S-4 ↗Merger, acquisition or tender offer
- Aug 21, 26Form 4 ↗Insider transaction
- Aug 20, 26Form 144 ↗Notice of proposed sale
- Aug 14, 26SCHEDULE 13G/A ↗Passive stake · T. Rowe Price Associates, Inc. · 3.1% · event on Jun 30, 26 · amendment
1,292 filings on record, the oldest from Jul 17, 95.
Listing the 25 most recent filings of the 1,292 on record.
15641
- Oct 6, 26Completed an acquisition or disposal+2 more in the same filing8-K 2.01 ↗
- Sep 15, 26A senior executive left or was appointed8-K 5.02 ↗
- Jul 22, 26Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Jan 6, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Sep 2, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Sep 18, 24Past accounts declared unreliable and being restated+3 more in the same filing8-K 4.02 ↗
- Jun 14, 24A senior executive left or was appointed8-K 5.02 ↗
- Mar 19, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Dec 15, 23Sold unregistered shares+3 more in the same filing8-K 3.02 ↗
- Dec 7, 23Sold unregistered shares+2 more in the same filing8-K 3.02 ↗
4 senior executive changes2022 – 2023show all 4hide
- Oct 2, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Sep 12, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Feb 9, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jun 1, 22A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Mar 8, 22Entered a material agreement+1 more in the same filing8-K 1.01 ↗
9 older filings not shown · The record reaches back to Nov 18, 04.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- FMR LLC13.0%Sep 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- BlackRock, Inc.9.3%Mar 31, 25SCHEDULE 13G/A ↗
- Vanguard Capital Management5.0%Jun 30, 26SCHEDULE 13G ↗
- Roy T. Eddleman Living Trust4.8%Dec 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- T. Rowe Price Associates, Inc.3.1%Jun 30, 26SCHEDULE 13G/A ↗3 earlier filings
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Oct 5, Loeillot Olivier filed notice of intent to sell up to $798K. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $1.0M across 2 trades on Oct 5, per their Form 4. Their sales over those 90 days add up to 132% of the amount announced. 5 other notices of theirs overlap this window.
View notice (Form 144) ↗+7 more recent notices · 6 with a later sale
- Oct 5, 26Sell$238KOlivier LoeillotChief Executive Officer↗
- Oct 5, 26Sell$798KOlivier LoeillotChief Executive Officer↗
- Sep 24, 26Sell$1.6MOlivier LoeillotChief Executive Officer↗
- Sep 24, 26Sell$863KOlivier LoeillotChief Executive Officer↗
- Sep 21, 26Sell$977KOlivier LoeillotChief Executive Officer↗
- Sep 4, 26Sell$504KOlivier LoeillotChief Executive Officer↗
- Aug 20, 26Sell$977KOlivier LoeillotChief Executive Officer↗
- Jul 16, 26Sell$80KJason K GarlandCFO↗
- Jun 25, 26Sell$106KJason K GarlandCFO↗
- Apr 21, 26Sell$536KOlivier LoeillotChief Executive Officer↗
Stock compensation, tax and giftsshow the 30 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Oct 6, 26Compensationamount n/aBrian Robb DouglassCHIEF PRODUCT OFFICER↗
- Oct 5, 26Compensation$651KOlivier LoeillotChief Executive Officer↗
- Oct 2, 26Tax$227KOlivier LoeillotChief Executive Officer↗
- Sep 25, 26Tax$80KJason K GarlandCFO↗
- Sep 24, 26Compensation$1.3MOlivier LoeillotChief Executive Officer↗
- Sep 24, 26Compensation$706KOlivier LoeillotChief Executive Officer↗
- Sep 21, 26Compensation$769KOlivier LoeillotChief Executive Officer↗
- Sep 3, 26Tax$482KOlivier LoeillotChief Executive Officer↗
- Sep 1, 26Tax$47KVioletta HughesCHIEF ACCOUNTING OFFICER↗
- Aug 20, 26Compensation$769KOlivier LoeillotChief Executive Officer↗
- May 14, 26Compensationamount n/aNICOLAS BARTHELEMY↗
- May 14, 26Compensationamount n/aKAREN A DAWES↗
- May 14, 26Compensationamount n/aMargaret Pax↗
- May 14, 26Compensationamount n/aRohin Mhatre↗
- May 14, 26Compensationamount n/aGLENN P MUIR↗
- May 14, 26Compensationamount n/aMANNER CARRIE EGLINTON↗
- May 14, 26Compensationamount n/aMartin D Madaus↗
- May 14, 26Compensationamount n/aKonstantin Konstantinov↗
- May 7, 26Tax$42KBrian Robb DouglassCHIEF PRODUCT OFFICER↗
- May 7, 26Compensation$94KGLENN P MUIR↗
- Mar 5, 26Compensationamount n/aJason K GarlandCFO↗
- Mar 5, 26Compensationamount n/aJames BylundChief Operating Officer↗
- Mar 5, 26Compensationamount n/aOlivier LoeillotChief Executive Officer↗
- Mar 5, 26Compensationamount n/aRALF KURIYELSenior VP, R&D↗
- Mar 5, 26Compensationamount n/aVioletta HughesCHIEF ACCOUNTING OFFICER↗
- Mar 4, 26Compensationamount n/aRALF KURIYELSenior VP, R&D↗
- Mar 4, 26Tax$5KRALF KURIYELSenior VP, R&D↗
- Mar 4, 26Compensationamount n/aJames BylundChief Operating Officer↗
- Mar 4, 26Tax$8KJames BylundChief Operating Officer↗
- Mar 2, 26Tax$28KBrian Robb DouglassCHIEF PRODUCT OFFICER↗
The full record holds 252 transactions and goes back to Feb 6, 23.
Its sector and its market
Repligen Corporation among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Repligen Corporation, the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Repligen Corporation in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 1,292 documents on file, from Jul 17, 1995 to Oct 8, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.